Advertisement
Advertisement
U.S. markets open in 4 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Pherecydes Pharma Société anonyme (ALPHE.PA)

Paris - Paris Delayed Price. Currency in EUR
2.3600+0.0600 (+2.61%)
As of 10:47AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3000
Open2.3300
BidN/A x N/A
AskN/A x N/A
Day's Range2.2900 - 2.3850
52 Week Range1.8600 - 6.9490
Volume1,320
Avg. Volume3,515
Market Cap16.978M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ALPHE.PA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Pherecydes Pharma Announces Its Participation in Several Scientific and Investor Conferences

      NANTES, France, January 25, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announced today that its management team will participate in the following scientific and investor events:

    • Business Wire

      Pherecydes Pharma Announces its Financial Agenda for 2023

      NANTES, France, January 03, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced its financial agenda for 2023.

    • Business Wire

      Pherecydes Pharma: Minutes of the Combined General Meeting of December 15, 2022

      NANTES, France, December 15, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that the Combined General Meeting of December 15, 2022 was able to deliberate, the quorum having been reached.

    Advertisement
    Advertisement